Notice to Readers Availability of Updated HIV Treatment Guidelines
Two HIV-related treatment guidelines have been updated. "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents," prepared by the U.S. Department of Health and Human Services and the Henry J. Kaiser Foundation Panel on Clinical Practices for Treatment of HIV Infection, has been updated several times since publication in MMWR (1). The most recent update contains information about the newly licensed nucleoside reverse transcriptase inhibitor, abacavir (ZiagenTM*).
In addition, the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, comprising specialists caring for HIV-infected infants, children, and adolescents, has updated "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (2). These guidelines include information about the use of abacavir (ZiagenTM) and the use of efavirenz (SustivaTM), a non-nucleoside reverse transcriptase inhibitor, for treating HIV infection in children. Also included is updated information about the newly available liquid preparation of nevirapine (ViramuneTM) for pediatric use.
The updates are available from the World-Wide Web site of the HIV/AIDS Treatment Information Service (ATIS) at http://www.hivatis.org,** or from ATIS, telephone (800) 448-0440.
References
CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(no. RR-5).
CDC. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998; 47(no. RR-4).
* Use of trade names and commercial sources does not imply endorsement by the U.S. Department of Health and Human Services or CDC.
** References to sites of nonfederal organizations on the World-Wide Web are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
